NFATc1-IN-1 (compound A04) 一种是 RANKL- 诱导的破骨细胞 (osteoclast) 形成的有效抑制剂，其IC50为 1.57 μM。NFATc1-IN-1 通过降低 RANKL 诱导的NFATc1核转位，显示抗破骨细胞 (anti-osteoclastogenic) 作用。NFATc1-IN-1 可用于破骨疾病的研究。

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC 50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research [1].

NFATc1-IN-1 (compound A04) (0-2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption [1]. NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1 [1]. Cell Viability Assay [1] Cell Line: Osteoclast precursor RAW 264.7 cells Concentration: 0, 0.5, 1.0, 1.5, 2.0 and 2.5 μM Incubation Time: 4 days Result: Markedly reduced the number and size of red TRAP-positive multinucleated osteoclasts at concentrations of 1.5, 2.0, and 2.5 μM. Significantly inhibited formation of osteoclasts in a dose-dependent manner (at 1.5, 2.0 and 2.5 μM), while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM. Immunofluorescence [1] Cell Line: RAW264.7 cells Concentration: 1.5 or 2.5 μM Incubation Time: 24 h Result: Blocked NFATc1 nuclear translocation and decreased the level of NFATc1.

1912422-56-0

C13H8F2INO2

375.11

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years